Another traders plan gave a quote of $340 for a three month supply. I would imagine most plans will land somewhere in between. A small price to pay when one considers the debilitating effect PBA has on one's social/family life. On a related note, a new survey was recently released (presumably in effort to create PBA awareness) detailing data concerning the aforementioned debilitating impact of PBA (see here ). Avanir has yet to tip their hand concerning plans to seek EMA approval, nor have they provided any updates since their 11/01/10 conference call concerning talks with potential EU partners. Avanir has not yet responded to my recent inquiries into such. There has been healthy debate among investors as to which Avanir should pursue first, EU approval or an EU partnership. Whichever Avanir decides, the news would certainly give Avanir's share price a boost, if Nuedexta's US sales doesn't do that first. It is becoming evident that the market for Avanir's drug and/or the companys ability to deliver on